CAPR

Capricor Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-17

Figures on this page computed 2026-11-08 12:40 UTC

Last close

9.00USD

Market data, 2026-11-06

Except where said otherwise: 10-K for 2025, filed 2026-03-17

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001104659-26-029580
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-17
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-029580
Reported in
USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-14
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-14
The filing itself
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-029580
Reported in
USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-029580
Reported in
USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001104659-26-029580
Reported in
USD
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-14
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.06 against 0.50 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.00x

3.89x

3.36x

n/a

0.92x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-06

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-17

Sales0.00x
Its own average over 10 years, 6.0M.
Profit3.89x
Its own average over 10 years, -27.0M.
Free cash flow3.36x
Its own average over 10 years, -21.6M.
Debtn/a
Its own average over 4 years, 4.7M.
Price0.92x
Its own average over 11 years, 10. Market data, 2026-11-06

Profit is furthest from its own average, at 3.89 times.

Sales is 0.00 times its own 10-year average; Profit is 3.89 times its own 10-year average; Free cash flow is 3.36 times its own 10-year average; Price is 0.92 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-17

Sales against its own 10-year average0.00
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-029580
Reported in
USD
The filing itself
Profit against its own 10-year average3.89
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-029580
Reported in
USD
The filing itself
Free cash flow against its own 10-year average3.36
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-029580
Reported in
USD
The filing itself
Debt against its own 4-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-029580
Reported in
USD
The filing itself
Price against its own 11-year average0.92Market data, 2026-11-06
Source
market
Taken on
2026-11-06
Reported in
USD